Business
OWC Pharmaceutical Research Advances Its Multiple Myeloma Study to Animals
OWC Pharmaceutical Research Advances Its Multiple Myeloma Study to Animals.
About this update from Owc Pharmaceutical Research Corp
[{"type":"text","content":"\n\n\n\nOWC Pharmaceutical Research Advances Its Multiple Myeloma Study to Animals\n\n\n\n\n\nOWC Pharmaceutical Research Advances Its Multiple Myeloma Study to Animals\nWith In-Vitro Testing Complete, Company Starts Protocol For Pre-Clinical Efficacy and Safety Testing On Mice\nPR Newswire\nPETACH TIKVA, Israel, March 29, 2016\n\n\n\nPETACH TIKVA, Israel, March 29, 2016 /PRNewswire/ --\n\nOWC Pharmaceutical Research Corp. (OTCQB: OWCP), (\"OWC\" or the \"Company\"), an Israeli-based developer of cannabinoid-based therapies targeting a variety of different indications, today announced that it has completed in-vitro testing on its formulation for multiple myeloma and is preparing to begin pre-clinical safety and efficacy studies on mice.\n\n     (Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )\n\n     (Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )\n\nThe Company's in-vitro testing indicated that specific formulations of CBD and THC decreased survival of multiple myeloma cells in a concentration-dependent manner, and resulted in 100% malignant cell death in 60% of cases. This formulation will now be tested in a pre-clinical, IRB approved protocol on mice in an effort to duplicate those results.\n\n\"The preliminary results of the in-vitro studies of our cannabinoid formulation on multiple myeloma were very positive, so we have decided to advance the study on live animals, in this case mice. We hope that the efficacy and safety will give us the comfort we need to continue on to the human stage of testing.\" said Dr. Yehuda Baruch, OWC's Director of Research.  \n\nDr. Baruch continued, \"Multiple myeloma is a cancer of plasma cells in the bone marrow, and accounts for 2% of all cancer deaths. Each successful round of testing on our cannabinoid-centric formulations brings us closer to changing the way we treat patients suffering from this deadly disease.\"\n\nAbout OWC Pharmaceutical Research Corp.    \n\nOWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively \"OWC\" or the \"Company\") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also devel...